Gordian Capital Singapore Pte Ltd Makes New $277,000 Investment in Danaher Co. (NYSE:DHR)

Gordian Capital Singapore Pte Ltd acquired a new stake in Danaher Co. (NYSE:DHR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,110 shares of the conglomerate’s stock, valued at approximately $277,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Tsfg LLC lifted its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher in the 1st quarter valued at $30,000. Finally, Richardson Financial Services Inc. bought a new stake in Danaher in the fourth quarter valued at $42,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $274.54 on Wednesday. The firm’s 50 day moving average price is $270.98 and its two-hundred day moving average price is $258.24. The stock has a market cap of $203.35 billion, a PE ratio of 46.53, a PEG ratio of 4.55 and a beta of 0.83. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. As a group, analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DHR shares. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.